15 April 2022>: Clinical Research
A Single-Center Retrospective Study of Selected Clinical Parameters and Intraoperative Fluid Management of Patients Undergoing Pancreatoduodenectomy
Patryk Zemła 1BCDEF* , Justyna Bajak 1BEF , Bartosz Molasy 12BEF , Łukasz Krzych 3E , Sławomir Mrowiec 4E , Katarzyna Kuśnierz 4ADEFDOI: 10.12659/MSM.936114
Med Sci Monit 2022; 28:e936114
Table 2 Patients’ characteristics, intraoperative parameters, comorbidities, and pre-surgery ERCP by sex.
Comorbidities | Frequency (n=192) | Frequency in females (n=87) | Frequency in males (n=105) |
---|---|---|---|
Diabetes | 57 (29.7%) | 25 (28.7%) | 32 (30.5%) |
Cardiovascular diseases | 107 (55.7%) | 46 (52.9%) | 61 (58.1%) |
Respiratory diseases | 13 (6.8%) | 6 (6.9%) | 7 (6.7%) |
Renal diseases | 37 (19.3%) | 17 (19.5%) | 20 (19.0%) |
CNS diseases | 16 (8.3%) | 7 (8.0%) | 9 (8.6%) |
Pancreatic diseases | 12 (6.3%) | 5 (5.7%) | 7 (6.7%) |
Thyroid diseases | 20 (10.4%) | 15 (17.2%) | 5 (4.8%) |
Smoking | 43 (22.4%) | 16 (18.4%) | 27 (25.7%) |
ERCP | 49 (25.5%) | 17 (19.5%) | 32 (30.5%) |
Age >50 years | 159 (82.8%) | 70 (80.5%) | 89 (84.8%) |
Age >60 years | 101 (52.6%) | 45 (51.7%) | 56 (53.3%) |
Obesity (≥30 BMI) | 20 (10.5%) | 12 (13.8%) | 8 (7.8%) |
Catecholamine supply* | 29 (15.1%) | 12 (13.8%) | 17 (16.2%) |
RBC concentrate supply* | 53 (27.6%) | 25 (28.7%) | 28 (27.2%) |
FFP supply* | 44 (22.9%) | 18 (20.7%) | 26 (25.2%) |
RBC concentrate postoperative supply | 47 (24.7%) | 26 (29.9%) | 21 (20.4%) |
Fluid therapy (>7.9 ml/kg/h)* | 80 (50.0%) | 46 (64.8%) | 34 (38.2%) |
ASA PS I | 9 (4.7%) | 6 (7.0%) | 3 (2.8%) |
ASA PS II | 110 (57.3%) | 46 (53.5%) | 64 (60.4%) |
ASA PS III | 65 (33.9%) | 31 (36%) | 34 (32.1%) |
ASA PS IV | 8 (4.1%) | 3 (3.5%) | 5 (4.7%) |
n – number of patients; CNS – central nervous system; ERCP – endoscopic retrograde cholangiopancreatography; RBC – red blood cell; FFP – fresh frozen plasma; BMI – Body Mass Index; ASA PS – The American Society of Anesthesiologists Physical Status. * Intraoperative parameters. |